Tacrolimus [clinicaltrials_resource:NCT00895583/group/E2]
Participants received tacrolimus (extended-release formulation not permitted) within 30 days of transplant, dosed according to center’s standard of care. At 3-5 months post-transplant, participants were randomized and tacrolimus continued. Participants remained on an IMPDH inhibitor (MMF or MPS; switching between the two was permitted). Corticosteroids were maintained at a minimum of 2.5 mg/day of prednisone (or equivalent); withdrawal was prohibited after randomization. Participants received study drug during the post-randomization period for up to a maximum of 18 months post-transplant.
Total, other adverse events for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/102/count/204]Leukopenia for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/103/count/206]Polycythaemia for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/104/count/208]Apthous stomatitis for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/105/count/210]Diarrhoea for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/106/count/212]Mouth ulceration for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/107/count/214]Nausea for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/108/count/216]Stomatitis for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/109/count/218]Vomiting for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/110/count/220]Oedema peripheral for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/111/count/222]Pyrexia for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/112/count/224]Nasopharyngitis for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/113/count/226]Upper respiratory tract infection for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/114/count/228]Urinary tract infection for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/115/count/230]Blood creatinine increased for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/116/count/232]Weight increased for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/117/count/234]Dyslipidemia for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/118/count/236]Hypercholesterolaemia for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/119/count/238]Hyperglycaemia for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/120/count/240]Hyperlipidaemia for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/121/count/242]Hypokalaemia for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/122/count/244]Pain in extremity for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/123/count/246]Headache for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/124/count/248]Tremor for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/125/count/250]Proteinuria for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/126/count/252]Cough for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/127/count/254]Oropharyngeal pain for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/128/count/256]Acne for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/129/count/258]Hypertension for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/other_events/130/count/260]Total, serious adverse events for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/1/count/2]Diarrhoea for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/10/count/20]Hypertension for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/100/count/200]Hypertensive crisis for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/101/count/202]Flatulence for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/11/count/22]Gingivitis ulcerative for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/12/count/24]Mouth ulceration for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/13/count/26]Small intestinal obstruction for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/14/count/28]Chest discomfort for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/15/count/30]Chest pain for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/16/count/32]Granuloma for NCT00895583 for E2 in NCT00895583 [clinicaltrials_resource:NCT00895583/serious_events/17/count/34]
group [clinicaltrials_vocabulary:group]
Tacrolimus [clinicaltrials_resource:NCT00895583/group/E2]
Participants received tacrolimus (extended-release formulation not permitted) within 30 days of transplant, dosed according to center’s standard of care. At 3-5 months post-transplant, participants were randomized and tacrolimus continued. Participants remained on an IMPDH inhibitor (MMF or MPS; switching between the two was permitted). Corticosteroids were maintained at a minimum of 2.5 mg/day of prednisone (or equivalent); withdrawal was prohibited after randomization. Participants received study drug during the post-randomization period for up to a maximum of 18 months post-transplant.
Bio2RDF identifier
NCT00895583/group/E2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00895583/group/E2
group id [clinicaltrials_vocabulary:group-id]
description
Participants received tacrolim ...... of 18 months post-transplant.
@en
identifier
clinicaltrials_resource:NCT00895583/group/E2
title
Tacrolimus
@en
type
label
Tacrolimus [clinicaltrials_resource:NCT00895583/group/E2]
@en